By Stephen Nakrosis

Shares of Marker Therapeutics Inc. jumped in after-hours trading Thursday, following news the U.S. Food and Drug Administration approved the company's investigational new drug application for MT-601 to treat certain patients with non-Hodgkin lymphoma.

At 5:54 p.m. ET, the company's shares were trading 100% higher at 66 cents a share. Volume in the after-hours market was over 2.4 million shares.

Peter L. Hoang, the company's president and chief executive, said, "FDA clearance of our IND for MT-601 is a significant milestone as we advance our pipeline in a number of company-sponsored trials." He added that MT-601 targets six tumor-associated antigens highly expressed in lymphoma, and said, "we look forward to initiating our company-sponsored Phase 1 study next year."

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

August 04, 2022 18:13 ET (22:13 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Marker Therapeutics Charts.
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Marker Therapeutics Charts.